In two years, Dassault Systèmes changed its scope.
From a group mainly focused on manufacturing industries, it has become a leading global player in the health sector.
Not that it suddenly started producing drugs, but because its solutions and software are increasingly used by pharmaceutical companies for research and therapeutic trials.
"BioNTech has extended its contracts with Dassault Systèmes to extend its research in the field of the fight against Covid-19 and its variants",
explains Bernard Charlès, the CEO of the group.
Moderna has also extended its relationship with DS.
"We have become number one in the field of therapeutic research with more than 22,000 clinical trials around the world which are based on Dassault Systèmes / Medidata platforms",
specifies the CEO.
The simulation tools developed by the group are used to virtualize clinical trials, accelerate research by
This article is for subscribers only.
You have 76% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in